Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Fallopian Tube Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Neoplasms 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Vaccinia 1Uterine Cervical Neoplasms 1Solid Tumors 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1HER2-negative Breast Cancer 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Small Cell 1Breast Diseases 1Brain Neoplasms 1Biliary Tract Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Cisplatin 7Etoposide 6pembrolizumab 4Topotecan 4Pemetrexed 4Carboplatin 4Gemcitabine 3belinostat 2Temozolomide 2RRx-001 2Paclitaxel 2vosaroxin 1vinflunine 1veliparib 1taxane 1sagopilone 1sacituzumab govitecan 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1bemiparin 1belotecan 1atezolizumab 1apalutamide 1alvocidib 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × taxane × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡